Related search

HLA-A24 and Survivin: Possibilities in Therapeutic Vaccination Against Cancer

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2006English

A Phase I Clinical Trial of Vaccination With KIF20A-derived Peptide in Combination With Gemcitabine for Patients With Advanced Pancreatic Cancer

Journal of immunotherapy (Hagerstown, Md. : 1997)
Cancer ResearchAllergyImmunologyPharmacology
2014English

Phase I Clinical Trial of Multiple-Peptide Vaccination for Patients With Advanced Biliary Tract Cancer

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2014English

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2015English

Randomized Phase II Trial Designs With Biomarkers

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

Erratum To: Phase I Clinical Trial of Vaccination With URLC10-derived Peptide for Patients With Advanced Esophageal Cancer

Esophagus
Gastroenterology
2012English

Phase II Trial of Vatalanib in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma After First-Line Gemcitabine Therapy (PCRT O4-001)

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2014English

Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated After Chemoradiotherapy and an 8-Year Update on a Phase I/Ii Trial

Clinical Cancer Research
Cancer ResearchOncology
2011English

Identification of a Novel HLA-A24-restricted Cytotoxic T Lymphocyte Epitope Peptide Derived From Mesothelin in Pancreatic Cancer

Oncotarget
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy